Medicine
Descovy 200 mg/25 mg tablet
Descovy 200 mg/25 mg tablet is a prescription medicine containing Emtricitabine and Tenofovir alafenamide for oral use, marketed by Gilead Sciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Key facts
- Active ingredient (INN)
- Emtricitabine and Tenofovir alafenamide
- Brand
- Descovy
- Strength
- 200 mg/25 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- Gilead Sciences
- Manufacturer
- Gilead Sciences
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AR17 Emtricitabine and Tenofovir alafenamide
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 April 2016
- Identifiers
- RxCUI 1747691, 1747697, 2590641 +1DailyMed set ID 06f66e98-e6ee-4538-9506-6c1282cc14c1NDC 61958-2002Application NDA208215
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet in 1 bottle, plastic | 61958-2002-1 | Gilead Sciences | 4 April 2016 |
| 30 tablet in 1 blister pack | 61958-2002-2 | Gilead Sciences | 22 January 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Emtricitabine and Tenofovir alafenamide
Clinical summary
Emtricitabine and Tenofovir alafenamide is a fixed-dose combination of a human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor and a hepatitis B virus nucleoside analog reverse transcriptase inhibitor. MedsAcross supplies Emtricitabine and Tenofovir alafenamide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Emtricitabine and Tenofovir alafenamideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- DESCOVY prescribing information (Gilead Sciences) · U.S. National Library of Medicine, DailyMed
- Descovy: European public assessment report (EPAR) · European Medicines Agency
- Emtricitabine / Tenofovir alafenamide Viatris: European public assessment report (EPAR) · European Medicines Agency
Need Descovy 200 mg/25 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.